{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:35:54Z","timestamp":1764333354779,"version":"3.28.0"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das asbestbedingte maligne Mesotheliom (MM) geh\u00f6rt in Deutschland mit ca. 1000 Neuerkrankungen pro Jahr zu den h\u00e4ufigen berufsbedingten Krebserkrankungen. Die Diagnose eines MM ist, sofern die entsprechenden diagnostischen Kriterien erf\u00fcllt sind, sowohl aus histologischem als auch aus zytologischem Probenmaterial mit hoher Spezifit\u00e4t m\u00f6glich. Allerdings werden viele MM zyto-\/histologisch erst in fortgeschrittenen Stadien entdeckt. Klinisch\/radiologische Aspekte erg\u00e4nzen die Diagnostik und erm\u00f6glichen eine interdisziplin\u00e4re Beurteilung des Tumorstadiums und individuelle Entscheidungen \u00fcber die bestm\u00f6glichen Therapieoptionen f\u00fcr jeden einzelnen Patienten. Diagnostisch hat die videoassistierte Thorakoskopie (VATS) den h\u00f6chsten Stellenwert. Die Therapieplanung orientiert sich am vorliegenden MM-Subtyp, der Tumorausbreitung und Stadium sowie dem klinischen Zustand des Patienten. Die Prognose des MM ist im Allgemeinen sehr ung\u00fcnstig. Dementsprechend zielt die Standardtherapie auf eine makroskopische radikale Tumorresektion im Sinne einer Zytoreduktion im Rahmen eines geeigneten multimodalen Therapiekonzepts (Chemotherapie, Strahlentherapie, Psychoonkologie). Ziel palliativer Ma\u00dfnahmen sollte v.a. die Symptomkontrolle sein. Insgesamt ist die interdisziplin\u00e4re Diagnostik und Therapie des MM entscheidend f\u00fcr die bestm\u00f6gliche Versorgung der MM-Kranken.\n    <\/jats:p>","DOI":"10.1055\/a-2202-5445","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:44:33Z","timestamp":1704411873000},"page":"262-268","source":"Crossref","is-referenced-by-count":2,"title":["Interdisziplin\u00e4re Diagnostik und Therapie von malignen Mesotheliomen"],"prefix":"10.1055","volume":"78","author":[{"given":"Lea I. S.","family":"van der Linde","sequence":"additional","affiliation":[{"name":"Zytopathologie, Institut f\u00fcr Pathologie Universit\u00e4t Hamburg, Hamburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Hantzsch-Kuhn","sequence":"additional","affiliation":[{"name":"Onkologie, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ellebrecht","sequence":"additional","affiliation":[{"name":"Onkologie, LungenClinic Grosshansdorf GmbH, Grosshansdorf, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Stellmacher","sequence":"additional","affiliation":[{"name":"H\u00e4matopathologie, Institut f\u00fcr H\u00e4matopathologie, Hamburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Welker","sequence":"additional","affiliation":[{"name":"Zytopathologie, Institut f\u00fcr Pathologie Universit\u00e4t Hamburg, Hamburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1183\/09031936.96.09091932","article-title":"The epidemiology of mesothelioma in historical context","volume":"9","author":"J McDonald","year":"1996","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1055\/a-1404-1562","article-title":"Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms \u2013 Ein Experten-Konsensuspapier [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma \u2013 An Expert Consensus Paper]","volume":"75","author":"C Aigner","year":"2021","journal-title":"Pneumologie"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3238\/arztebl.2013.0319","article-title":"Malignant mesothelioma \u2013 German mesothelioma register 1997\u20131999","volume":"74","author":"V Neumann","year":"2001","journal-title":"Int Arch Occup Environ Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"V Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"ref5","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"C Bianchi","year":"1997","journal-title":"Eur J Cancer Prev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant Pleural Mesothelioma A Population-Based Study of Survival","volume":"5","author":"M Milano","year":"2010","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"A Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"A Scherpereel","year":"2010","journal-title":"Euro Respir J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"AN Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"volume-title":"Hyalurons\u00e4uremessung im Pleuraerguss \u2013 Diagnostischer Parameter maligner Mesotheliome. Dissertation","year":"2005","author":"M M\u00fcller","key":"ref10"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura:\n          Advances since the 2004 Classification","volume":"11","author":"F Galateau-Salle","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ajcp\/110.2.135","article-title":"The Diagnosis of Desmoplastic Malignant Mesothelioma","volume":"110","author":"TV Colby","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"AG Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"W Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00428-007-0375-x","article-title":"Cytological diagnosis of malignant mesothelioma \u2013 improvement by additional analysis of hyaluronic acid in pleural effusions","volume":"450","author":"L Welker","year":"2007","journal-title":"Virchows Arch"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/5584_2021_680","article-title":"Cytological Diagnostic Procedures in Malignant Mesothelioma","volume":"1374","author":"C Biancosino","year":"2022","journal-title":"Adv Exp Med Biol"},{"volume-title":"WHO Reporting System for Lung Cytopathology, Ed. IAC-IARC Cytopathology. Reporting Systems. 1th Edition. Bd 1","year":"2022","key":"ref17"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000377697","article-title":"Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma","volume":"59","author":"A Hjerpe","year":"2015","journal-title":"Acta Cytologica"},{"key":"ref19","first-page":"847","volume-title":"Diffuse Malignant Mesothelioma","author":"VW Rusch","year":"2009"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/cancers14041044","article-title":"Current Management and Future Perspective in Pleural Mesothelioma","volume":"14","author":"R Shah","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.athoracsur.2021.04.078","article-title":"Extrapleural Pneumonectomy Versus Pleurectomy\/Decortication for Malignant Pleural\n          Mesothelioma","volume":"113","author":"N Zhou","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1200\/JCO.2016.34.15_suppl.8554","article-title":"Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis","volume":"34","author":"SA Srour","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1200\/JCO.2019.37.15_suppl.8517","article-title":"Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance)","volume":"37","author":"AZ Dudek","year":"2019","journal-title":"J Clin Oncol"},{"issue":"S 05","key":"ref24","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"Switch maintenance gemcitabine after first line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19). Poster presented at: European Society for Medical Oncology. Annual Meeting; 27 September\u20131 October 2019, Barcelona, Spain","volume":"30","author":"JA Burgers","year":"2019","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"G Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"P375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"The Lancet"},{"issue":"S 05","key":"ref27","doi-asserted-by":"publisher","first-page":"S1341","DOI":"10.1016\/j.annonc.2021.08.2146","article-title":"LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743","volume":"32","author":"S Peters","year":"2021","journal-title":"Annals of Oncology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"A Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISEmeso trial","volume":"31","author":"S Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"N Bayman","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2202-5445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:42:08Z","timestamp":1730810528000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2202-5445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":30,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2202-5445","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"type":"print","value":"0934-8387"},{"type":"electronic","value":"1438-8790"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}